deltatrials
Completed PHASE3 INTERVENTIONAL 8-arm NCT04440163

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE

Sponsor: Pfizer

Updated 22 times since 2020 Last updated: Mar 22, 2023 Started: Jun 17, 2020 Primary completion: Jul 24, 2022 Completion: Jul 24, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Meningococcal Vaccine, this trial is completed. The trial is conducted by Pfizer and has accumulated 22 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

22 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. May 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2023 — May 2023 [monthly]

    Completed PHASE3

Show 17 earlier versions
  1. Dec 2022 — Feb 2023 [monthly]

    Completed PHASE3

  2. Nov 2022 — Dec 2022 [monthly]

    Completed PHASE3

  3. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  4. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Jan 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  7. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  8. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  9. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  10. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  11. Mar 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  12. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  13. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  14. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  15. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  16. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  17. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .